C
Caleb Lee
Researcher at Daiichi Sankyo
Publications - 33
Citations - 2196
Caleb Lee is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Trastuzumab & Metastatic breast cancer. The author has an hindex of 9, co-authored 33 publications receiving 950 citations. Previous affiliations of Caleb Lee include Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi,Cristina Saura,Toshinari Yamashita,Yeonhee Park,Sung Bae Kim,Kenji Tamura,Fabrice Andre,Hiroji Iwata,Yoshinori Ito,Junji Tsurutani,Junji Tsurutani,Joohyuk Sohn,Neelima Denduluri,Christophe Perrin,Kenjiro Aogi,Eriko Tokunaga,Seock-Ah Im,Keun Seok Lee,Sara A. Hurvitz,Javier Cortes,Caleb Lee,Shuquan Chen,Lin Zhang,Javad Shahidi,Antoine Yver,Ian E. Krop +25 more
TL;DR: Tastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer and requires attention to pulmonary symptoms and careful monitoring.
Journal ArticleDOI
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi,Haeseong Park,Rashmi Krishna Murthy,Hiroji Iwata,Kenji Tamura,Junji Tsurutani,Alvaro Moreno-Aspitia,Toshihiko Doi,Yasuaki Sagara,Charles H. Redfern,Ian E. Krop,Caleb Lee,Yoshihiko Fujisaki,Masahiro Sugihara,Lin Zhang,Javad Shahidi,Shunji Takahashi +16 more
TL;DR: The novel Her2-targeted ADC, T-DXd, demonstrated promising preliminary antitumor activity in patients with HER2-low breast cancer and should be monitored closely and proactively managed.
Journal ArticleDOI
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi,Kohei Shitara,Yoichi Naito,Akihiko Shimomura,Yasuhiro Fujiwara,Kan Yonemori,Chikako Shimizu,Tatsunori Shimoi,Yasutoshi Kuboki,Nobuaki Matsubara,Atsuko Kitano,Takahiro Jikoh,Caleb Lee,Yoshihiko Fujisaki,Yusuke Ogitani,Antoine Yver,Kenji Tamura +16 more
TL;DR: In this small, heavily pretreated study population, trastuzumab deruxtecan showed antitumour activity, even in low HER2-expressing tumours, and the most likely recommended phase 2 dosing is 5·4 or 6·4 mg/kg.
Journal ArticleDOI
Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura,Junji Tsurutani,Junji Tsurutani,Shunji Takahashi,Hiroji Iwata,Ian E. Krop,Charles H. Redfern,Yasuaki Sagara,Toshihiko Doi,Haeseong Park,Rashmi Krishna Murthy,Rebecca Redman,Takahiro Jikoh,Caleb Lee,Masahiro Sugihara,Javad Shahidi,Antoine Yver,Shanu Modi +17 more
TL;DR: Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in trastuzuumab emtansine-pretreated patients with HER2-positive breast cancer, which suggest that further development in phase 2 and 3 clinical trials for Her2- positive breast cancer is warranted.
Journal ArticleDOI
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
J. Cortés,S-B Kim,W-P. Chung,S-A. Im,Young-Ae Park,Roberto Hegg,Min Kim,L-M Tseng,V. Petry,C-F. Chung,H. Iwata,Erika Hamilton,Giuseppe Curigliano,B H Xu,Caleb Lee,Yali Liu,J. Cathcart,Emarjola Bako,Sunil Verma,Sara A. Hurvitz +19 more